Yash Chemex Ltd Valuation Shifts to Very Attractive Amid Mixed Market Performance

Valuation Metrics Signal Improved Price Attractiveness

Yash Chemex’s current P/E ratio stands at 24.73, a figure that, while not low in absolute terms, is significantly more appealing when compared to its historical averages and peer group valuations. The company’s P/BV ratio of 1.45 further underscores this improved valuation stance, suggesting that the stock is trading closer to its book value than in previous periods. This contrasts sharply with several peers in the miscellaneous sector, many of which are trading at elevated multiples.

For context, Titan Biotech and Sanstar, two notable competitors, are valued at P/E ratios of 66.25 and 72.5 respectively, categorising them as very expensive and expensive stocks. Even Stallion India, with a P/E of 26.52, trades at a premium relative to Yash Chemex. This comparative analysis highlights Yash Chemex’s repositioning as a more affordable option within its industry.

Enterprise Value Multiples and Profitability Ratios

Examining enterprise value (EV) multiples, Yash Chemex’s EV to EBITDA ratio is 26.23, which, while elevated, remains competitive against peers such as Sanstar (72.62) and Titan Biotech (53.99). The EV to EBIT ratio of 27.16 also reflects a valuation that is more reasonable relative to these companies. However, the company’s return on capital employed (ROCE) and return on equity (ROE) remain modest at 4.37% and 4.46% respectively, indicating room for operational improvement.

Despite these moderate profitability metrics, the company’s PEG ratio of 0.05 is particularly noteworthy. This extremely low PEG suggests that the stock’s price is undervalued relative to its earnings growth potential, signalling a potential opportunity for investors willing to look beyond short-term earnings volatility.

Stock Price Performance and Market Context

Yash Chemex’s share price has experienced a significant correction in recent weeks, closing at ₹56.01 on 30 Mar 2026, down 6.45% from the previous close of ₹59.87. The stock’s 52-week high was ₹111.00, while the low was ₹46.54, indicating considerable volatility. This price movement has contributed to the improved valuation multiples, as the market adjusts to both company-specific and broader sectoral factors.

When compared to the Sensex, Yash Chemex’s returns have been mixed. Over the past week and month, the stock has underperformed the benchmark, with declines of 6.99% and 10.83% respectively, versus Sensex drops of 1.27% and 9.48%. Year-to-date, the stock has fallen 28.79%, more than double the Sensex’s 13.66% decline. However, over a one-year horizon, Yash Chemex has delivered a positive return of 16.69%, outperforming the Sensex’s negative 5.18% return. Longer-term returns over three and five years remain below the benchmark, reflecting the company’s cyclical challenges and sector dynamics.

Micro-Cap Status and Market Perception

Yash Chemex is classified as a micro-cap stock, which often entails higher volatility and risk but also the potential for outsized returns. The company’s Mojo Score currently stands at 34.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 25 Mar 2026. This upgrade reflects a modest improvement in the company’s outlook, driven largely by valuation adjustments rather than fundamental earnings growth.

Investors should note that while the valuation has become very attractive, the company’s operational metrics such as ROCE and ROE remain subdued, and the stock’s recent price weakness signals caution. The micro-cap nature also implies liquidity constraints and higher susceptibility to market sentiment swings.

Peer Comparison Highlights Valuation Edge

Among its peers, Yash Chemex’s valuation stands out as very attractive. Companies such as Gulshan Polyols and TGV Sraac also share this rating, with P/E ratios of 20.95 and 7.05 respectively, and EV to EBITDA multiples of 9.91 and 3.34. While Yash Chemex’s multiples are higher, its PEG ratio of 0.05 is lower than these peers, indicating a potentially undervalued growth trajectory.

Conversely, firms like Titan Biotech and Sanstar remain very expensive, with P/E ratios exceeding 60 and EV to EBITDA multiples above 50. This disparity suggests that investors seeking value within the miscellaneous sector may find Yash Chemex a more compelling proposition, provided they are comfortable with the associated risks.

Investment Considerations and Outlook

Yash Chemex’s transition to a very attractive valuation grade offers a window of opportunity for value-oriented investors. The stock’s low PEG ratio and reasonable P/BV multiple relative to peers support a thesis of undervaluation. However, the company’s modest profitability ratios and micro-cap status warrant a cautious approach.

Investors should weigh the potential for operational improvements against the risks of market volatility and sector-specific headwinds. The recent upgrade from Strong Sell to Sell by MarketsMOJO reflects this nuanced outlook, signalling that while the stock is no longer a strong sell, it still requires careful monitoring.

Overall, Yash Chemex Ltd’s valuation shift is a significant development that merits attention, especially for those seeking exposure to micro-cap stocks with potential upside from current price levels.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today